CN107206090A - 阿匹莫德在结肠直肠癌治疗中的用途 - Google Patents

阿匹莫德在结肠直肠癌治疗中的用途 Download PDF

Info

Publication number
CN107206090A
CN107206090A CN201580072610.5A CN201580072610A CN107206090A CN 107206090 A CN107206090 A CN 107206090A CN 201580072610 A CN201580072610 A CN 201580072610A CN 107206090 A CN107206090 A CN 107206090A
Authority
CN
China
Prior art keywords
composition
apimod
colorectal cancer
cancer
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580072610.5A
Other languages
English (en)
Chinese (zh)
Inventor
N.比哈里
S.盖尔
S.兰德雷特
P.贝克特
C.康拉
T.徐
M.埃尔南德斯
J.M.罗思伯格
H.利钦斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAM Therapeutics Inc
Original Assignee
LAM Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAM Therapeutics Inc filed Critical LAM Therapeutics Inc
Publication of CN107206090A publication Critical patent/CN107206090A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580072610.5A 2014-11-07 2015-11-06 阿匹莫德在结肠直肠癌治疗中的用途 Pending CN107206090A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US62/077127 2014-11-07
US201562115228P 2015-02-12 2015-02-12
US62/115228 2015-02-12
US201562119540P 2015-02-23 2015-02-23
US62/119540 2015-02-23
PCT/US2015/059526 WO2016073884A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
CN107206090A true CN107206090A (zh) 2017-09-26

Family

ID=54548301

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580072610.5A Pending CN107206090A (zh) 2014-11-07 2015-11-06 阿匹莫德在结肠直肠癌治疗中的用途
CN201580072613.9A Expired - Fee Related CN107427522B (zh) 2014-11-07 2015-11-06 用于治疗黑素瘤的阿吡莫德

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580072613.9A Expired - Fee Related CN107427522B (zh) 2014-11-07 2015-11-06 用于治疗黑素瘤的阿吡莫德

Country Status (16)

Country Link
US (2) US20190209576A1 (https=)
EP (3) EP3215157B8 (https=)
JP (2) JP6768682B2 (https=)
KR (2) KR20170098813A (https=)
CN (2) CN107206090A (https=)
AU (2) AU2015342876B2 (https=)
BR (2) BR112017009265A2 (https=)
CA (2) CA2966334A1 (https=)
ES (1) ES2734081T3 (https=)
HU (1) HUE044153T2 (https=)
IL (2) IL251904B (https=)
MX (2) MX374385B (https=)
PL (1) PL3215157T3 (https=)
PT (1) PT3215157T (https=)
RU (2) RU2739992C2 (https=)
WO (2) WO2016073871A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20190015421A1 (en) * 2016-01-21 2019-01-17 Lam Therapeutics, Inc. Biomarkers for Treating Cancer with Apilimod
KR20190067824A (ko) * 2016-10-12 2019-06-17 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 알츠하이머병 치료에 사용하기 위한 방법
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
EP4351585A1 (en) * 2021-06-11 2024-04-17 Orphai Therapeutics Inc. Stabilized apilimod compositions and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
CN106659716A (zh) * 2014-01-24 2017-05-10 拉姆医疗公司 阿吡莫德组合物及其使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
EA009873B1 (ru) 2004-02-06 2008-04-28 Элан Фармасьютикалз, Инк. Способ ингибирования роста опухоли и/или метастатического прогрессирования
JP4926943B2 (ja) * 2004-04-13 2012-05-09 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２産生を阻害する二塩
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
PT2038252T (pt) 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
US10206910B2 (en) * 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
US20180015098A1 (en) * 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) * 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
CN106659716A (zh) * 2014-01-24 2017-05-10 拉姆医疗公司 阿吡莫德组合物及其使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNE-MARIEBAIRD，等: "IL-23R is epigenetically regulated and modulated by chemotherapy in Non-Small Cell Lung Cancer", 《FRONTIERS IN ONCOLOGY》 *
FENG LAN，等: "IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma", 《INT J COLORECTAL DIS》 *
KEPENG WANG，等: "Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases", 《ANN RHEUM DIS》 *
YUMIKO WADA，等: "Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis", 《PLOS ONE》 *

Also Published As

Publication number Publication date
HUE044153T2 (hu) 2019-09-30
IL251904A0 (en) 2017-06-29
EP3215159B1 (en) 2021-07-21
EP3215159A1 (en) 2017-09-13
US20190209576A1 (en) 2019-07-11
IL251904B (en) 2021-03-25
CN107427522A (zh) 2017-12-01
WO2016073871A1 (en) 2016-05-12
EP3954375A1 (en) 2022-02-16
RU2017119064A (ru) 2018-12-10
CA2966356A1 (en) 2016-05-12
AU2015342863A1 (en) 2017-06-15
PT3215157T (pt) 2019-07-12
CN107427522B (zh) 2021-06-15
RU2739992C2 (ru) 2020-12-30
JP6768682B2 (ja) 2020-10-14
JP2017535600A (ja) 2017-11-30
WO2016073884A1 (en) 2016-05-12
AU2015342876A1 (en) 2017-06-15
RU2017119066A (ru) 2018-12-07
BR112017009000A2 (pt) 2017-12-19
KR20170098813A (ko) 2017-08-30
JP2017533963A (ja) 2017-11-16
ES2734081T3 (es) 2019-12-04
AU2015342876B2 (en) 2020-07-09
KR20170101907A (ko) 2017-09-06
CA2966334A1 (en) 2016-05-12
US20170333439A1 (en) 2017-11-23
RU2017119064A3 (https=) 2019-06-03
MX2017006026A (es) 2017-06-19
PL3215157T3 (pl) 2019-11-29
RU2017119066A3 (https=) 2019-06-07
RU2731908C2 (ru) 2020-09-09
BR112017009265A2 (pt) 2017-12-19
AU2015342863B2 (en) 2021-01-21
EP3215157B1 (en) 2019-04-10
US10765682B2 (en) 2020-09-08
EP3215157A1 (en) 2017-09-13
EP3215157B8 (en) 2019-05-22
MX2017006019A (es) 2017-09-13
IL251903B (en) 2021-05-31
MX374385B (es) 2025-03-06
IL251903A0 (en) 2017-06-29
JP6716585B2 (ja) 2020-07-01

Similar Documents

Publication Publication Date Title
US11266654B2 (en) Apilimod compositions and methods for using same
EP3215159B1 (en) Apilimod for use in the treatment of colorectal cancer
US20200253979A1 (en) Therapeutic methods relating to hsp90 inhibitors
CN107249638B (zh) 阿匹莫德用于治疗肾癌
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer
HK1242204B (en) Apilimod for use in the treatment of melanoma
HK1242204A1 (en) Apilimod for use in the treatment of melanoma
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Connecticut, USA

Applicant after: Artificial Intelligence Treatment Co.

Address before: Connecticut, USA

Applicant before: LAM THERAPEUTICS, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170926